Kidney Res Clin Pract.
2022 Jul;41(4):432-441. 10.23876/j.krcp.21.261.
Mayo imaging classification is a good predictor of rapid progress among Korean patients with autosomal dominant polycystic kidney disease: results from the KNOW-CKD study
- Affiliations
-
- 1Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Seoul, Republic of Korea
- 2Kidney Research Institute, Hallym University College of Medicine, Seoul, Republic of Korea
- 3Rehabilitation Medical Research Center, Korea Workers’ Compensation and Welfare Service Incheon Hospital, Incheon, Republic of Korea
- 4Department of Radiology, Seoul National University Hospital, Seoul, Republic of Korea
- 5Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea
- 6Department of Prevention and Management, Inha University School of Medicine, Incheon, Republic of Korea
- 7Department of Internal Medicine, Inje University Busan Paik Hospital, Busan, Republic of Korea
- 8Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
- 9Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Republic of Korea
- 10Department of Internal Medicine, National Medical Center, Seoul, Republic of Korea
- 11Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Republic of Korea
- KMID: 2535389
- DOI: http://doi.org/10.23876/j.krcp.21.261
Abstract
- Background
Mayo imaging classification (MIC) is a useful biomarker to predict disease progression in autosomal dominant polycystic kidney disease (ADPKD). This study was performed to validate MIC in the prediction of renal outcome in a prospective Korean ADPKD cohort and evaluate clinical parameters associated with rapid disease progression. Methods: A total of 178 ADPKD patients were enrolled and prospectively observed for an average duration of 6.2 ± 1.9 years. Rapid progressor was defined as MIC 1C through 1E while slow progressor was defined as 1A through 1B. Renal composite outcome (doubling of serum creatinine, 50% decline of estimated glomerular filtration rate [eGFR], or initiation of renal replacement therapy) as well as the annual percent change of height-adjusted total kidney volume (mHTKV-α), and eGFR decline (mGFR-α) were compared between groups. Results: A total of 110 patients (61.8%) were classified as rapid progressors. These patients were younger and showed a higher proportion of male patients. Rapid progressor was an independent predictor for renal outcome (hazard ratio, 4.09; 95% confidence interval, 1.23–13.54; p = 0.02). The mGFR-α was greater in rapid progressors (–3.58 mL/min per year in 1C, –3.7 in 1D, and –4.52 in 1E) compared with that in slow progressors (–1.54 in 1A and –2.06 in 1B). The mHTKV-α was faster in rapid progressors (5.3% per year in 1C, 9.4% in 1D, and 11.7% in 1E) compared with that in slow progressors (1.2% in 1A and 3.8% in 1B). Conclusion: MIC is a good predictive tool to define rapid progressors in Korean ADPKD patients.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Management of autosomal dominant polycystic kidney disease in the era of disease-modifying treatment options
- Using the Mayo Imaging Classification to predict renal outcomes in Korean autosomal dominant polycystic kidney disease patients
- Are you ready to accompany autosomal dominant polycystic kidney disease patients in their treatment journey? Real practice for selecting rapid progressors and treatment with tolvaptan
- A Case of Renal Cell Carcinoma in Autosomal Dominant Polycystic Kidney Disease Hemodialyzed
- Autosomal Dominant Polycystic Kidney Disease: 2009 Update for Internists
